Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Short term Debt (2022 - 2025)

BioXcel Therapeutics (BTAI) has 3 years of Short term Debt data on record, last reported at $16.8 million in Q3 2025.

  • For Q3 2025, Short term Debt changed N/A year-over-year to $16.8 million; the TTM value through Sep 2025 reached $16.8 million, changed N/A, while the annual FY2022 figure was $422000.0, N/A changed from the prior year.
  • Short term Debt reached $16.8 million in Q3 2025 per BTAI's latest filing, up from $11.2 million in the prior quarter.
  • Across five years, Short term Debt topped out at $16.8 million in Q3 2025 and bottomed at $56000.0 in Q1 2022.
  • Average Short term Debt over 3 years is $3.7 million, with a median of $576000.0 recorded in 2022.
  • The widest YoY moves for Short term Debt: up 578.57% in 2023, down 171.38% in 2023.
  • A 3-year view of Short term Debt shows it stood at $422000.0 in 2022, then soared by 72.99% to $730000.0 in 2023, then surged by 2204.52% to $16.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $16.8 million in Q3 2025, $11.2 million in Q2 2025, and $5.6 million in Q1 2025.